AOD-9604 vs Semaglutide

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

AOD-9604 (anti-obesity drug 9604; Tyr-hGH(177–191)) is a synthetic 16-amino-acid peptide corresponding to the C-terminal lipolytic fragment of human growth hormone, modified with an N-terminal tyrosine residue for stability, and investigated as a candidate anti-obesity compound on the premise that the lipolytic activity of hGH resides in this C-terminal domain — separable from the growth-promoting and insulin-antagonizing effects mediated by other regions of the full-length molecule. AOD-9604 is proposed to stimulate fat metabolism through beta-3 adrenergic receptor-mediated pathways without activating IGF-1 production or the anabolic receptor domains of full-length GH, making it theoretically safer than GH itself for metabolic applications; a 2001 preclinical study in obese mice (PMID 11713213) demonstrated lipolytic effects and body weight reduction via this mechanism. Clinical trials were conducted in humans by Metabolic Pharmaceuticals, and Phase 2/3 data generated in Australia suggested modest weight loss effects; however, the primary trial results were never published in PubMed-indexed peer-reviewed journals, and the best indexed primary evidence for AOD-9604 remains that preclinical mouse study. AOD-9604 has no FDA approval and no approved indication in any jurisdiction; despite its human clinical program, the absence of published peer-reviewed primary trial data means clinical efficacy and safety cannot be independently evaluated, and no validated human dosing protocol has been established. The compound is currently available only as a research peptide. AOD-9604 is supplied as a lyophilized powder for research use; oral formulations were also evaluated in the clinical program as an alternative to subcutaneous delivery, though no commercial oral AOD-9604 product reached market. AOD-9604 evidence limitations The primary indexed evidence base for AOD-9604 consists of a 2001 preclinical study in obese mice (PMID 11713213) demonstrating beta-3 adrenergic receptor-mediated lipolysis and body weight reduction without IGF-1 elevation or blood glucose disruption. The Phase 2/3 human clinical program conducted by Metabolic Pharmaceuticals generated obesity trial data, but those primary results were never published in PubMed-indexed peer-reviewed journals, meaning the human efficacy and safety dataset cannot be independently evaluated. No validated human dosing protocol has been established for AOD-9604 in any jurisdiction, and no approved clinical indication exists. The absence of published human trial data represents a fundamental gap that precludes definitive statements about clinical efficacy, optimal administration, or long-term safety. AOD-9604 side effects and safety profile The safety data from AOD-9604's clinical program includes several notable findings: no elevation in IGF-1 levels was observed at studied doses — a key distinction from full-length growth hormone, where IGF-1 elevation drives concerns about cell proliferation and potential oncogenicity. No significant disruption of fasting glucose or insulin sensitivity was documented. No serious adverse events attributable to AOD-9604 were reported in published trial summaries. The absence of anabolic receptor activity (no binding to the GH receptor growth-promoting domain) is the proposed basis for this benign safety profile compared to GH itself. Long-term safety data does not exist due to the absence of Phase 3 completion and product approval. Research-grade AOD-9604 carries standard purity and contamination risks associated with unregulated compounding. Providers offering AOD-9604 through supervised clinical programs are searchable in the PeptideBase provider directory.

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake. Its extended half-life of approximately seven days is achieved via structural modifications including a C18 fatty diacid chain enabling reversible albumin binding.

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). It is among the most prescribed and searched compounds in the weight loss space. Compounding pharmacies have produced semaglutide formulations under 503A and 503B frameworks, with significant provider interest across the telehealth and functional medicine space. Mechanism of action: Semaglutide activates glucagon-like peptide-1 (GLP-1) receptors in the hypothalamus, brainstem, and pancreas. This triggers a coordinated metabolic response: appetite signals are reduced, gastric emptying is slowed (increasing satiety duration), insulin secretion is potentiated in a glucose-dependent manner, and glucagon secretion is suppressed. The result is reduced caloric intake and improved postprandial glucose regulation. Semaglutide's extended half-life (~7 days) enables once-weekly subcutaneous injection, distinguishing it from earlier GLP-1 agonists that required daily dosing. Clinical evidence: The STEP trial program established semaglutide's weight reduction profile. STEP 1 (2021) found a mean weight reduction of 14.9% over 68 weeks with 2.4mg/week semaglutide (Wegovy dose) vs 2.4% with placebo. STEP 4 demonstrated that discontinuation led to weight regain, indicating ongoing use is required to maintain outcomes. The SUSTAIN trial series confirmed cardiovascular risk reduction in T2D patients. Semaglutide is one of the most extensively studied GLP-1 agonists in large-scale randomised controlled trials. Semaglutide with B12: Some compounding formulations combine semaglutide with vitamin B12 (methylcobalamin) in the same injectable preparation. The rationale is two-fold: nausea and gastrointestinal discomfort are the most commonly reported side effects of GLP-1 agonists (occurring in 15–40% of users in trials), and injectable methylcobalamin bypasses the reduced gastric absorption that can accompany slowed gastric motility. B12 also supports energy metabolism during periods of caloric restriction. Clinical evidence that B12 addition changes weight loss outcomes is limited; the combination is primarily a compounding convention rather than a protocol validated in independent clinical trials. Providers offering compounded semaglutide with B12 formulations are indexed in the PeptideBase directory. Semaglutide vs tirzepatide: Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors. The SURMOUNT-5 head-to-head trial found tirzepatide produced greater weight reductions than semaglutide at comparable doses. Both are FDA-approved and available through licensed prescribers; protocol selection depends on clinical context and provider judgment.